BRYAN VEKOVIUS, M.D.
Neuro-ophthalmology Physician in SHREVEPORT, Louisiana. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
BRYAN VEKOVIUS, M.D. filed 3,964 Medicare Part D claims in 2023 as a Neuro-ophthalmology Physician in SHREVEPORT, Louisiana, prescribing 76% generic.
- 4K
- Part D claims, 2023
- 76%
- generic prescribing
- $11.0K
- industry payments (Sunshine Act)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
BRYAN VEKOVIUS, M.D.'s Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2023 — across all CMS prescribers nationally
3,964 Top 9% higher than 91% of 1,370,886 prescribers
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Medicare Part D Prescriber Public Use File · 2023
BRYAN VEKOVIUS, M.D. practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about BRYAN VEKOVIUS, M.D.?
Quality data not reportedPrimary specialty
Medicare Part D claims
Specialty distribution in Louisiana
How Neuro-ophthalmology Physician compares to other specialties among Louisiana providers
Neuro-ophthalmology Physician share within Louisiana
Neuro-ophthalmology Physician is one of the more visible NUCC categories in Louisiana
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Specialty board-certification context
Estimated specialty board-certified rate — Neuro-ophthalmology Physician (ABMS / AOA reference)
- Est. board-certified rate
- 78%
- Neuro-ophthalmology Physician ABMS/AOA estimate
Est. board-certified rate (Neuro-ophthalmology Physician) — ABMS / AOA estimate
Verify credentials
- Verify via ABMS free public lookup
- Verify via AOA osteopathic boards
- Specialty volume Neuro-ophthalmology Physician US NPIs
Specialty board-certified rate — Neuro-ophthalmology Physician estimate
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus Maintenance of Certification cycles. CMS does not publish a per-provider board-certification field; the figure shown is the specialty-level estimated rate from ABMS / AOA reference data.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
BRYAN VEKOVIUS, M.D. appears in the CMS NPPES registry as a Neuro-ophthalmology Physician provider holding M.D. credentials at 450 ASHLEY RIDGE BLVD, SHREVEPORT, LA, 71106, with a listed phone of (318) 375-3733. NPI 1285674820 was issued on 06/08/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what VEKOVIUS most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 3,964 prescription claims written by this provider, covering 937 Medicare beneficiaries and totaling roughly $3.2 million in drug spend, split 24% brand-name and 76% generic by claim count, with an opioid prescribing rate of 6.5%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.
Neuro-ophthalmology Physician is a narrow specialty nationwide, with 128 enrolled providers across 34 states and an average of 419 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1285674820 |
|---|---|
| Specialty | Neuro-ophthalmology Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 06/08/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm BRYAN VEKOVIUS, M.D.'s current license status, disciplinary history, and board certifications with the Louisiana State Board of Medical Examiners in Louisiana before relying on this page for a clinical or care decision.
How we sourced this profile
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for BRYAN VEKOVIUS, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$11.0K
Largest payer
Amgen Inc.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Brand vs generic prescribing mix · Typical
24% brand-name claims vs 76% generic, on 3,964 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 5,015
- Total Day Supply
- 113,881
- Brand vs Generic
- 24% brand / 76% generic
- Brand Drug Cost
- $3.1M
- Generic Drug Cost
- $60K
- Opioid Claims
- 258 (6.5% rate)
- Antibiotic Claims
- 186
Patient Demographics
- Average Patient Age
- 73.1 years
- Avg HCC Risk Score
- 1.22
- Gender Split
- 62% female / 38% male
- Age Distribution
- <65: 103, 65-74: 408, 75-84: 328, 85+: 98
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What BRYAN VEKOVIUS, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Erythromycin
Erythromycin
965 claims
- Latanoprost
Latanoprost
579 claims
- Ondansetron Hcl 282
Ondansetron Hcl
282 claims
- Hydrocodone-Acetam… 233
Hydrocodone-Acetaminophen
233 claims
- Restasis 168
Restasis
168 claims
- Pyridostigmine Bro… 134
Pyridostigmine Bromide
134 claims
- Doxycycline Hyclate 119
Doxycycline Hyclate
119 claims
- Mycophenolate Mofe… 104
Mycophenolate Mofetil
104 claims
| Drug | Claims |
|---|---|
| Erythromycin Erythromycin Base | 965 |
| Latanoprost | 579 |
| Ondansetron Hcl | 282 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 233 |
| Restasis Cyclosporine | 168 |
| Pyridostigmine Bromide | 134 |
| Doxycycline Hyclate | 119 |
| Mycophenolate Mofetil | 104 |
| Prednisone | 101 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 99 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Neuro-ophthalmology Physician Overview
How BRYAN VEKOVIUS, M.D. fits within the Neuro-ophthalmology Physician landscape nationally.
BRYAN VEKOVIUS, M.D.'s 3,964 claims are above the specialty average of 419.
Nearby Neuro-ophthalmology Physician Providers in Louisiana
Other clinicians with the same primary specialty enrolled in Louisiana, drawn from the same CMS NPPES roster as VEKOVIUS.
Compare Neuro-ophthalmology Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Louisiana
Frequently Asked Questions
What is BRYAN VEKOVIUS, M.D.'s specialty? ▼
How much does BRYAN VEKOVIUS, M.D. prescribe under Medicare Part D? ▼
Where is BRYAN VEKOVIUS, M.D. located? ▼
What is BRYAN VEKOVIUS, M.D.'s NPI number? ▼
Does BRYAN VEKOVIUS, M.D. prescribe more brand-name or generic drugs? ▼
Does BRYAN VEKOVIUS, M.D. prescribe opioids? ▼
How many Neuro-ophthalmology Physician providers are there in the US? ▼
What drugs does BRYAN VEKOVIUS, M.D. prescribe most often? ▼
Does BRYAN VEKOVIUS, M.D. accept Medicare? ▼
How can I verify BRYAN VEKOVIUS, M.D.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology